BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24745685)

  • 1. Treatment strategies in mastocytosis.
    Siebenhaar F; Akin C; Bindslev-Jensen C; Maurer M; Broesby-Olsen S
    Immunol Allergy Clin North Am; 2014 May; 34(2):433-47. PubMed ID: 24745685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy.
    Paraskevopoulos G; Sifnaios E; Christodoulopoulos K; Mantopoulou F; Papakonstantis M; Sabaziotis D
    Eur Ann Allergy Clin Immunol; 2013 Apr; 45(2):52-5. PubMed ID: 23821833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic criteria and classification of mastocytosis in 2014.
    Akin C; Valent P
    Immunol Allergy Clin North Am; 2014 May; 34(2):207-18. PubMed ID: 24745670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mastocytosis: advances in diagnosis and treatment.
    Hungness SI; Akin C
    Curr Allergy Asthma Rep; 2007 Jul; 7(4):248-54. PubMed ID: 17547845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
    Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
    Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular defects in mastocytosis: KIT and beyond KIT.
    Bibi S; Langenfeld F; Jeanningros S; Brenet F; Soucie E; Hermine O; Damaj G; Dubreuil P; Arock M
    Immunol Allergy Clin North Am; 2014 May; 34(2):239-62. PubMed ID: 24745672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow cytometry in mastocytosis: utility as a diagnostic and prognostic tool.
    Sánchez-Muñoz L; Teodosio C; Morgado JM; Perbellini O; Mayado A; Alvarez-Twose I; Matito A; Jara-Acevedo M; García-Montero AC; Orfao A; Escribano L
    Immunol Allergy Clin North Am; 2014 May; 34(2):297-313. PubMed ID: 24745675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report.
    Sokol KC; Ghazi A; Kelly BC; Grant JA
    J Allergy Clin Immunol Pract; 2014; 2(3):266-70. PubMed ID: 24811015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mastocytosis: immunophenotypical features of the transformed mast cells are unique among hematopoietic cells.
    Horny HP; Sotlar K; Valent P
    Immunol Allergy Clin North Am; 2014 May; 34(2):315-21. PubMed ID: 24745676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
    Sotlar K
    Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.
    Cruse G; Metcalfe DD; Olivera A
    Immunol Allergy Clin North Am; 2014 May; 34(2):219-37. PubMed ID: 24745671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis.
    Kibsgaard L; Skjold T; Deleuran M; Vestergaard C
    Acta Derm Venereol; 2014 May; 94(3):363-4. PubMed ID: 24162824
    [No Abstract]   [Full Text] [Related]  

  • 13. Mast cell disorders: A framework of allergy and hematology symptoms leading to personalized treatments.
    Castells MC
    Ann Allergy Asthma Immunol; 2021 Oct; 127(4):403-404. PubMed ID: 34593102
    [No Abstract]   [Full Text] [Related]  

  • 14. Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
    Hadzijusufovic E; Peter B; Rebuzzi L; Baumgartner C; Gleixner KV; Gruze A; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Willmann M; Valent P
    Vet Immunol Immunopathol; 2009 Dec; 132(2-4):243-50. PubMed ID: 19505729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting c-kit in the therapy of mast cell disorders: current update.
    El-Agamy DS
    Eur J Pharmacol; 2012 Sep; 690(1-3):1-3. PubMed ID: 22789565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mastocytosis - an update.
    Amon U; Hartmann K; Horny HP; Nowak A
    J Dtsch Dermatol Ges; 2010 Sep; 8(9):695-711; quiz 712. PubMed ID: 20678151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mast cell disorders: Protean manifestations and treatment responses.
    Chen M; Kim A; Zuraw B; Doherty TA; Christiansen S
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):128-130. PubMed ID: 29604336
    [No Abstract]   [Full Text] [Related]  

  • 18. Mastocytosis: from a Molecular Point of View.
    Komi DEA; Rambasek T; Wöhrl S
    Clin Rev Allergy Immunol; 2018 Jun; 54(3):397-411. PubMed ID: 28725969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mastocytosis.
    Brockow K; Metcalfe DD
    Chem Immunol Allergy; 2010; 95():110-124. PubMed ID: 20519885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.
    Bibi S; Arock M
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):527-543. PubMed ID: 30007468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.